Doggrell Sheila A, Hancox Jules C
Doggrell Biomedical Communications, Auckland, New Zealand.
Expert Opin Investig Drugs. 2004 Apr;13(4):415-26. doi: 10.1517/13543784.13.4.415.
Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardiac side effects and this has driven development of amiodarone analogues. These analogues include short acting analogues (e.g., AT-2001) with similar acute effects to amiodarone, the thyroid receptor antagonist KB-130015 and dronedarone. Dronedarone, (SR-33589; Sanofi-Synthelabo), is a non-iodinated amiodarone derivative that inhibits Na +, K + and Ca 2+ currents. It is a potent inhibitor of the acetylcholine-activated K + current from atrial and sinoatrial nodal tissue, and inhibits the rapid delayed rectifier more potently than slow and inward rectifier K + currents and inhibits L-type calcium current. Dronedarone is an antagonist at alpha- and beta-adrenoceptors and unlike amiodarone, has little effect at thyroid receptors. Dronedarone is more potent than amiodarone in inhibiting arrhythmias and death in animal models of ischaemia- and reperfusion-induced arrhythmias. In the Dronedarone Atrial Fibrillation Study After Electrical Cardioversion (DAFNE) clinical trial, dronedarone 800 mg/day appeared to be effective and safe for the prevention of atrial fibrillation relapses after cardioversion. The Antiarrhythmic Trial with Dronedarone in Moderate-to-Severe Congestive Heart Failure Evaluating Morbidity Decrease (ANDROMEDA) trial was stopped due to a potential increased risk of death in the dronedarone group. Trials of dronedarone in the maintenance of sinus rhythm in patients with atrial fibrillation and a safety and tolerability study in patients with an implantable cardioverter defibrillator are ongoing. Further experimental and clinical studies are required before we have a definitive answer to whether dronedarone has advantages over amiodarone and other amiodarone analogues.
在目前使用的抗心律失常药物中,胺碘酮是最有效的药物之一,且药物诱发心律失常的风险相对较低,这可能归因于其对心脏离子通道和受体具有多种药理作用。然而,胺碘酮会引发显著的心脏外副作用,这推动了胺碘酮类似物的研发。这些类似物包括与胺碘酮具有相似急性效应的短效类似物(如AT - 2001)、甲状腺受体拮抗剂KB - 130015以及决奈达隆。决奈达隆(SR - 33589;赛诺菲 - 安万特)是一种非碘化的胺碘酮衍生物,可抑制钠、钾和钙电流。它是心房和窦房结组织中乙酰胆碱激活的钾电流的强效抑制剂,对快速延迟整流钾电流的抑制作用比对缓慢内向整流钾电流更强,并且抑制L型钙电流。决奈达隆是α和β肾上腺素能受体拮抗剂,与胺碘酮不同,它对甲状腺受体几乎没有作用。在缺血和再灌注诱导的心律失常动物模型中,决奈达隆在抑制心律失常和死亡方面比胺碘酮更有效。在电复律后决奈达隆治疗心房颤动研究(DAFNE)临床试验中,每日800毫克决奈达隆似乎对预防电复律后心房颤动复发有效且安全。评估发病率降低的决奈达隆治疗中重度充血性心力衰竭抗心律失常试验(ANDROMEDA)因决奈达隆组潜在的死亡风险增加而停止。决奈达隆用于心房颤动患者维持窦性心律的试验以及植入式心脏复律除颤器患者的安全性和耐受性研究正在进行。在我们确定决奈达隆是否优于胺碘酮及其他胺碘酮类似物之前,还需要进一步的实验和临床研究。